Mariana Tioni News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mariana tioni. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mariana Tioni Today - Breaking & Trending Today
Press release content from Business Wire. The AP news staff was not involved in its creation. Meissa Announces Preclinical Data on Intranasal COVID-19 Vaccine Showing Protection from SARS-CoV-2 Challenge after a Single Dose July 20, 2021 GMT REDWOOD CITY, Calif. (BUSINESS WIRE) Jul 19, 2021 Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the release of preclinical data in nonhuman primates (NHPs) of the company’s intranasal recombinant live attenuated COVID-19 vaccine (MV-014-212). The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2 challenge compared to reported efficacy in NHP models of currently authorized vaccines. Furthermore, the data show that MV-014-212 stimulates mucosal (nasal IgA) antibodies in the upper respiratory tract, the major infection route for SARS-CoV-2, and systemic (serum neutralizin ....
Published: Jul 19, 2021 By Gail Dutton Martin Moore, Ph.D., CEO and co-founder of Meissa Vaccines, pictured above. Meissa Vaccines’ intranasal vaccine for COVID-19 equals the protection afforded by existing vaccines in the same class of subjects after only a single dose, according to data presented this week at the American Society of Virology annual meeting. The caveat is that the data is from preclinical, non-human primate studies. The data – also published on bioRxiv – indicates that the MV-014-212 vaccine-induced mucosal (nasal IgA) antibodies in the upper respiratory tract and systemic (serum neutralizing and binding IgG antibodies) in African green monkeys and provided protection when challenged by the wild-type SARS-CoV-2 virus. ....